H Sinzinger|P Fitscha|F Rauscha|J Kaliman - JoVE Visualize

Showing results (21-30 of 523) with videos related to

Pageof 53

Sort By:

Folia Haematologica (Leipzig, Germany : 1928)|January 1, 1988

Platelet derived growth factor (PDGF) and prostaglandins (PGE1, PGI2) as modulators of the atherogenetic processH Sinzinger, T Zidek, P Fitscha, et al.

Prostaglandins, Leukotrienes, and Essential Fatty Acids|July 1, 1988

Epoprostenol in patients with Raynaud's diseaseP Fitscha, J Kaliman, F Weidinger, et al.

British Journal of Clinical Pharmacology|November 1, 1987

Development of optimal infusion regimens for epoprostenol using radio labelled platelet uptake over atherosclerotic lesions in manH Sinzinger, P Fitscha, J Kaliman, et al.

Lancet (London, England)|March 17, 1990

Synergistic effect of prostaglandin E1 and isosorbide dinitrate in peripheral vascular diseaseH Sinzinger, P Fitscha, J O'Grady, et al.

Eicosanoids|January 1, 1991

13,14-dihydro-PGE1, an in-vivo metabolite of PGE1, decreases mitotic activity induced by corticosteroid administrationP Fitscha, F Rauscha, W Rogatti, et al.

Prostaglandins, Leukotrienes, and Medicine|August 1, 1987

Prostacyclin synthesis stimulating plasma factor in patients with peripheral vascular diseaseE Strobl-Jäger, P Fitscha, J Kaliman, et al.

Prostaglandins, Leukotrienes, and Essential Fatty Acids|December 1, 1989

Beneficial effect of long-term PGE1-treatment in left ventricular heart failureI Virgolini, J Kaliman, P Fitscha, et al.

Prostaglandins|June 1, 1987

Prostaglandin I2 reduces activation of human arterial smooth muscle cells in-vivoH Sinzinger, T Zidek, P Fitscha, et al.

Prostaglandins, Leukotrienes, and Medicine|March 1, 1985

The prostacyclin synthesis stimulating plasma factor is unchanged during acute angina pectorisH Sinzinger, J Kaliman, P Fitscha, et al.

Experimental Pathology|January 1, 1990

Additive benefit of PGI2 and PGE1 (via different mechanisms?) on inhibition of activation of human vascular smooth muscle cells?H Sinzinger, P Fitscha, O Wagner, et al.

Pageof 53

Showing results (21-30 of 523) with videos related to

Sort By:

Pageof 53

Folia Haematologica (Leipzig, Germany : 1928)|January 1, 1988

Platelet derived growth factor (PDGF) and prostaglandins (PGE1, PGI2) as modulators of the atherogenetic processH Sinzinger, T Zidek, P Fitscha, et al.

Prostaglandins, Leukotrienes, and Essential Fatty Acids|July 1, 1988

Epoprostenol in patients with Raynaud's diseaseP Fitscha, J Kaliman, F Weidinger, et al.

British Journal of Clinical Pharmacology|November 1, 1987

Development of optimal infusion regimens for epoprostenol using radio labelled platelet uptake over atherosclerotic lesions in manH Sinzinger, P Fitscha, J Kaliman, et al.

Lancet (London, England)|March 17, 1990

Synergistic effect of prostaglandin E1 and isosorbide dinitrate in peripheral vascular diseaseH Sinzinger, P Fitscha, J O'Grady, et al.

Eicosanoids|January 1, 1991

13,14-dihydro-PGE1, an in-vivo metabolite of PGE1, decreases mitotic activity induced by corticosteroid administrationP Fitscha, F Rauscha, W Rogatti, et al.

Prostaglandins, Leukotrienes, and Medicine|August 1, 1987

Prostacyclin synthesis stimulating plasma factor in patients with peripheral vascular diseaseE Strobl-Jäger, P Fitscha, J Kaliman, et al.

Prostaglandins, Leukotrienes, and Essential Fatty Acids|December 1, 1989

Beneficial effect of long-term PGE1-treatment in left ventricular heart failureI Virgolini, J Kaliman, P Fitscha, et al.

Prostaglandins|June 1, 1987

Prostaglandin I2 reduces activation of human arterial smooth muscle cells in-vivoH Sinzinger, T Zidek, P Fitscha, et al.

Prostaglandins, Leukotrienes, and Medicine|March 1, 1985

The prostacyclin synthesis stimulating plasma factor is unchanged during acute angina pectorisH Sinzinger, J Kaliman, P Fitscha, et al.

Experimental Pathology|January 1, 1990

Additive benefit of PGI2 and PGE1 (via different mechanisms?) on inhibition of activation of human vascular smooth muscle cells?H Sinzinger, P Fitscha, O Wagner, et al.

Pageof 53